Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Assets: 2019-2024

Historic Current Assets for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $187.4 million.

  • Silence Therapeutics' Current Assets fell 34.70% to $133.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.6 million, marking a year-over-year decrease of 34.70%. This contributed to the annual value of $187.4 million for FY2024, which is 81.64% up from last year.
  • Latest data reveals that Silence Therapeutics reported Current Assets of $187.4 million as of FY2024, which was up 81.64% from $103.2 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Current Assets peaked at $187.4 million during FY2024, and registered a low of $98.1 million during FY2020.
  • Over the past 3 years, Silence Therapeutics' median Current Assets value was $119.7 million (recorded in 2022), while the average stood at $136.7 million.
  • Its Current Assets has fluctuated over the past 5 years, first surged by 105.09% in 2020, then decreased by 13.80% in 2023.
  • Yearly analysis of 5 years shows Silence Therapeutics' Current Assets stood at $98.1 million in 2020, then rose by 21.08% to $118.8 million in 2021, then increased by 0.74% to $119.7 million in 2022, then fell by 13.80% to $103.2 million in 2023, then soared by 81.64% to $187.4 million in 2024.